To investigate whether RC48 effectively inhibits the viability of HER2-positive melanoma cells, A2058 and SK-MEL-28 cells were exposed to different concentrations of RC48 and trastuzumab for 72 h. This evidence concerns the gene ERBB2 and melanoma.